Published in Infect Immun on June 01, 1999
Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun (2005) 2.13
Strain and virulence diversity in the mouse pathogen Chlamydia muridarum. Infect Immun (2009) 1.36
Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice. Infect Immun (2005) 1.20
The infecting dose of Chlamydia muridarum modulates the innate immune response and ascending infection. Infect Immun (2004) 1.20
Inhibition of matrix metalloproteinases protects mice from ascending infection and chronic disease manifestations resulting from urogenital Chlamydia muridarum infection. Infect Immun (2006) 1.17
Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for development of live attenuated chlamydial vaccine strains. Infect Immun (2000) 1.07
A role for matrix metalloproteinase-9 in pathogenesis of urogenital Chlamydia muridarum infection in mice. Microbes Infect (2007) 1.05
Monitoring the T cell response to genital tract infection. Proc Natl Acad Sci U S A (2006) 1.03
Plasmid deficiency in urogenital isolates of Chlamydia trachomatis reduces infectivity and virulence in a mouse model. Pathog Dis (2013) 0.99
A Chlamydia trachomatis-specific Th2 clone does not provide protection against a genital infection and displays reduced trafficking to the infected genital mucosa. Infect Immun (2002) 0.99
Murine Chlamydia trachomatis genital infection is unaltered by depletion of CD4+ T cells and diminished adaptive immunity. J Infect Dis (2011) 0.96
Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis. Infect Immun (2000) 0.96
Immunological memory in B-cell-deficient mice conveys long-lasting protection against genital tract infection with Chlamydia trachomatis by rapid recruitment of T cells. Immunology (2001) 0.96
Animal models for studying female genital tract infection with Chlamydia trachomatis. Infect Immun (2013) 0.90
Plasmid CDS5 influences infectivity and virulence in a mouse model of Chlamydia trachomatis urogenital infection. Infect Immun (2014) 0.86
Genomic variant representation in a Chlamydia population is dynamic and adaptive with dependence on in vitro and in vivo passage. Pathog Dis (2015) 0.85
Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect Immun (2013) 0.82
Acquired homotypic and heterotypic immunity against oculogenital Chlamydia trachomatis serovars following female genital tract infection in mice. BMC Infect Dis (2005) 0.81
A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice. Vaccine (2013) 0.78
Rectal administration of a chlamydial subunit vaccine protects against genital infection and upper reproductive tract pathology in mice. PLoS One (2017) 0.77
Update on Chlamydia trachomatis Vaccinology. Clin Vaccine Immunol (2017) 0.75
A novel whole-bacterial enzyme linked-immunosorbant assay to quantify Chlamydia trachomatis specific antibodies reveals distinct differences between systemic and genital compartments. PLoS One (2017) 0.75
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun (1981) 18.13
New knowledge of chlamydiae and the diseases they cause. J Infect Dis (1975) 9.35
Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med (1989) 4.25
Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection. Infect Immun (1988) 3.55
Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect Immun (1983) 3.22
Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun (1997) 3.12
Neutralization of Chlamydia trachomatis infectivity with antibodies to the major outer membrane protein. Infect Immun (1982) 3.09
A new animal model for the study of Chlamydia trachomatis genital infections: infection of mice with the agent of mouse pneumonitis. J Infect Dis (1981) 3.06
Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect Immun (1994) 2.73
Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines. Infect Immun (1991) 2.62
Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect Immun (1995) 2.55
Chronic chlamydial genital infection in congenitally athymic nude mice. Infect Immun (1985) 2.54
Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. Infect Immun (1997) 2.43
Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J Immunol (1996) 2.31
Local Th1-like responses are induced by intravaginal infection of mice with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun (1995) 2.28
Postabortal Chlamydia trachomatis salpingitis: correlating risk with antigen-specific serological responses and with neutralization. J Infect Dis (1987) 2.14
Salpingitis in mice induced by human strains of Chlamydia trachomatis. Br J Exp Pathol (1986) 2.03
Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance. JAMA (1965) 1.97
Initial route of antigen administration alters the T-cell cytokine profile produced in response to the mouse pneumonitis biovar of Chlamydia trachomatis following genital infection. Infect Immun (1996) 1.94
Structures of and allelic diversity and relationships among the major outer membrane protein (ompA) genes of the four chlamydial species. J Bacteriol (1993) 1.90
The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis (1999) 1.84
Chlamydia trachomatis antigens: role in immunity and pathogenesis. Infect Agents Dis (1994) 1.84
The immunobiology and immunopathology of chlamydial infections. APMIS (1995) 1.72
Humoral immune response to chlamydial genital infection of mice with the agent of mouse pneumonitis. Infect Immun (1989) 1.72
Genetic susceptibility to chlamydial salpingitis and subsequent infertility in mice. J Reprod Fertil (1992) 1.53
Immune response in mice infected in the genital tract with mouse pneumonitis agent (Chlamydia trachomatis biovar). Infect Immun (1984) 1.51
Demonstration of delayed hypersensitivity in Chlamydia trachomatis salpingitis in monkeys: a pathogenic mechanism of tubal damage. J Infect Dis (1994) 1.36
Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J Immunol (1996) 1.16
Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan. Am J Ophthalmol (1967) 1.14
Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease. J Infect Dis (1997) 1.12
Human immune response and Chlamydia trachomatis infection. Rev Infect Dis (1985) 1.10
Poliovirus hybrids expressing neutralization epitopes from variable domains I and IV of the major outer membrane protein of Chlamydia trachomatis elicit broadly cross-reactive C. trachomatis-neutralizing antibodies. Infect Immun (1995) 1.06
The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. J Exp Med (1962) 0.91
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev (1994) 4.94
Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun (1986) 4.34
Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci U S A (1993) 4.28
Parasite-specified phagocytosis of Chlamydia psittaci and Chlamydia trachomatis by L and HeLa cells. Infect Immun (1978) 4.26
Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun (1997) 3.12
Requirements for ingestion of Chlamydia psittaci by mouse fibroblasts (L cells). Infect Immun (1976) 3.11
Lymphokine-mediated inhibition of Chlamydia replication in mouse fibroblasts is neutralized by anti-gamma interferon immunoglobulin. Infect Immun (1983) 2.77
Immediate toxicity of high multiplicities of Chlamydia psittaci for mouse fibroblasts (L cells). Infect Immun (1976) 2.76
Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun (1994) 2.58
A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun (1990) 2.55
Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease. Trends Microbiol (1994) 2.54
Lymphokine-mediated microbistatic mechanisms restrict Chlamydia psittaci growth in macrophages. J Immunol (1982) 2.40
Role in vivo for gamma interferon in control of pneumonia caused by Chlamydia trachomatis in mice. Infect Immun (1988) 2.30
Effect of interferon on the growth of Chlamydia trachomatis in mouse fibroblasts (L cells). Infect Immun (1983) 2.17
Kinetics of phagocytosis of Chlamydia psittaci by mouse fibroblasts (L cells): separation of the attachment and ingestion stages. Infect Immun (1978) 1.94
Lymphokine enhances oxygen-independent activity against intracellular pathogens. J Exp Med (1983) 1.93
Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis (1999) 1.79
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Tumor necrosis factor alpha is a cytotoxin induced by murine Chlamydia trachomatis infection. Infect Immun (1989) 1.54
Reactivation of persistent Chlamydia trachomatis infection in cell culture. Infect Immun (1995) 1.54
IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Immunol (1993) 1.53
Inhibition of Chlamydia psittaci in oxidatively active thioglycolate-elicited macrophages: distinction between lymphokine-mediated oxygen-dependent and oxygen-independent macrophage activation. Infect Immun (1983) 1.53
Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect (1999) 1.52
Cytochalasin B does not inhibit ingestion of Chlamydia psittaci by mouse fibroblasts (L cells) and mouse peritoneal macrophages. Infect Immun (1979) 1.48
T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Clin Exp Immunol (1996) 1.48
Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis (1998) 1.46
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Immunoelectron-microscopic quantitation of differential levels of chlamydial proteins in a cell culture model of persistent Chlamydia trachomatis infection. Infect Immun (1994) 1.41
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun (2001) 1.28
Arrays of hemispheric surface projections on Chlamydia psittaci and Chlamydia trachomatis observed by scanning electron microscopy. J Bacteriol (1979) 1.26
A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun (1998) 1.25
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20
Reactivation of chlamydial genital tract infection in mice. Infect Immun (1997) 1.17
Role for inducible nitric oxide synthase in protection from chronic Chlamydia trachomatis urogenital disease in mice and its regulation by oxygen free radicals. Infect Immun (2001) 1.15
Inducible nitric oxide synthase does not affect resolution of murine chlamydial genital tract infections or eradication of chlamydiae in primary murine cell culture. Infect Immun (1998) 1.14
Borrelia theileri: isolation from ticks (Boophilus microplus) and tick-borne transmission between splenectomized calves. Am J Vet Res (1985) 1.13
Effect of interferon on a primary conjunctival epithelial cell model of trachoma. Invest Ophthalmol Vis Sci (1991) 1.11
Cytokine-mediated indoleamine 2,3-dioxygenase induction in response to Chlamydia infection in human macrophage cultures. Infect Immun (1994) 1.10
In vitro expression of factor-mediated cytotoxic activity generated during the immune response to Chlamydia in the mouse. J Immunol (1985) 1.07
Differential susceptibility of chlamydiae to exogenous fibroblast interferon. Infect Immun (1983) 1.07
Chlamydial heat shock proteins and disease pathology: new paradigms for old problems? Infect Dis Obstet Gynecol (1999) 1.04
Seroreactivity to Chlamydia trachomatis Hsp10 correlates with severity of human genital tract disease. Infect Immun (2000) 1.04
Bdellovibrio host dependence: the search for signal molecules and genes that regulate the intraperiplasmic growth cycle. J Bacteriol (1992) 1.02
Interactions between macrophages and chlamydiae. Immunol Ser (1994) 0.99
Intracellular tryptophan pool sizes may account for differences in gamma interferon-mediated inhibition and persistence of chlamydial growth in polarized and nonpolarized cells. Infect Immun (1999) 0.99
Use of monoclonal antibodies to facilitate identification, cloning, and purification of Chlamydia trachomatis hsp10. J Clin Microbiol (1997) 0.97
Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis. Infect Immun (2000) 0.96
Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1. Cell Immunol (1995) 0.95
Perioperative brain shift and deep brain stimulating electrode deformation analysis: implications for rigid and non-rigid devices. Ann Biomed Eng (2012) 0.93
Immunity to Chlamydia: comparison of human infections and murine models. Res Immunol (1997) 0.92
Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis (2000) 0.92
Hemocyte population changes during the immune response of Aedes aegypti to inoculated microfilariae of Dirofilaria immitis. J Parasitol (1989) 0.92
Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. Am J Respir Cell Mol Biol (1992) 0.90
Interferon gamma induced production of indoleamine 2,3 dioxygenase in cultured human synovial cells. J Rheumatol (1994) 0.90
Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. Microbes Infect (2001) 0.89
Role of tryptophan in gamma interferon-mediated chlamydial persistence. Ann N Y Acad Sci (1994) 0.84
Differential effects of gamma interferon on Chlamydia trachomatis growth in polarized and nonpolarized human epithelial cells in culture. Infect Immun (1998) 0.83
Ultrasonic welding for fast bonding of self-aligned structures in lab-on-a-chip systems. Lab Chip (2015) 0.80
Chlamydial treatment failures: a persistent problem? J Eur Acad Dermatol Venereol (2001) 0.80
In vivo-activated mononuclear phagocytes and protective immunity to chlamydiae in mice. Infect Immun (1988) 0.80
Interferons: from virus inhibitor to modulator of amino acid and lipid metabolism. J Interferon Res (1987) 0.79
Differential modulation of lymphocyte proliferative responses and lymphokine secretion in mice during development of immunity to Chlamydia psittaci. Infect Immun (1989) 0.79
Inducible nitric oxide synthase regulates production of isoprostanes in vivo during chlamydial genital infection in mice. Infect Immun (2003) 0.79
Tryptophan metabolism in chronic inflammatory lung disease. J Lab Clin Med (1995) 0.78
The in vitro antimicrobial capacity of human colostrum against Chlamydia trachomatis. J Reprod Immunol (1998) 0.77
Lymphokine stimulated macrophages inhibit intracellular Chlamydia psittaci replication by mechanisms distinct from intracellular inhibition of Toxoplasma gondii replication. Adv Exp Med Biol (1983) 0.77
The effect of intracellular Chlamydia psittaci on lysosomal enzyme activities in mouse peritoneal macrophages. Acta Pathol Microbiol Immunol Scand C (1987) 0.76
Comparative studies on the melanization response of male and female mosquitoes against microfilariae. Dev Comp Immunol (1986) 0.76
Evaluation of purified Theileria annulata sporozoite antigen from the tick Hyalomma anatolicum anatolicum. Vet Parasitol (1986) 0.76
Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle. J Biol Response Mod (1990) 0.75
The challenge of defining disease. Science (2001) 0.75
Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-beta Ser. J Interferon Res (1989) 0.75